Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer cell"
DOI: 10.1016/j.ccell.2022.02.007
Abstract: Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), 514 patients with treatment-naïve advanced ESCC were randomized (1:1) to receive toripalimab or placebo… read more here.
Keywords: advanced esophageal; treatment advanced; treatment; esophageal squamous ... See more keywords
Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study
Sign Up to like & getrecommendations! Published in 2024 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-024-01990-2
Abstract: The potential benefit of neoadjuvant toripalimab plus axitinib in cases with clear cell renal cell carcinoma (ccRCC) and inferior vena cava tumor thrombus (IVC-TT) remains unclear. NEOTAX was a phase 2 study to investigate the… read more here.
Keywords: plus axitinib; tumor thrombus; toripalimab plus; cell ... See more keywords
Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China
Sign Up to like & getrecommendations! Published in 2025 at "PLOS One"
DOI: 10.1371/journal.pone.0328730
Abstract: Background With or without biomarker-directed toripalimab plus chemotherapy could bring significant clinical benefit and acceptable safety profile compared with chemotherapy as first-line treatment for patients with extensive-stage small-cell lung-cancer (ES-SCLC) were demonstrated in EXTENTORCH trial.… read more here.
Keywords: plus chemotherapy; toripalimab plus; directed toripalimab; cost ... See more keywords
Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1341584
Abstract: Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for locally advanced non-small-cell lung cancer (LA-NSCLC), whereas responses to anti-programmed cell death-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) are heterogeneous. Though consolidation ICI following… read more here.
Keywords: bulky; plus chemotherapy; toripalimab plus; consolidation ... See more keywords
Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2025.1591517
Abstract: Objective The aim of this study was to evaluate the cost-effectiveness of toripalimab plus chemotherapy compared to chemotherapy alone as first-line therapy for extensive-stage small cell lung cancer(ES-SCLC) from the Chinese medical perspective. Methods Our… read more here.
Keywords: therapy; plus chemotherapy; toripalimab plus; chemotherapy ... See more keywords
Toripalimab plus cetuximab combined with radiotherapy in a locally advanced platinum-based chemotherapy-insensitive nasopharyngeal carcinoma patient: a case report
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2024.1383250
Abstract: Background Locoregionally advanced nasopharyngeal carcinoma (NPC) is an epithelial malignancy that primarily occurs in East and Southeast Asia, and it is associated with relatively poor overall survival (OS). Currently, there is no reliably effective standard… read more here.
Keywords: case report; platinum based; radiotherapy; toripalimab plus ... See more keywords